Haleon Completes Share Buyback of 805,127 Shares

Haleon PLC Sponsored ADR ( (HLN) ) just unveiled an announcement.

On May 28, 2025, Haleon plc announced the completion of a share buyback transaction, purchasing 805,127 ordinary shares for cancellation. This transaction is part of the company’s ongoing buyback program initiated on March 28, 2025. The shares were bought at prices ranging from 414.70p to 419.10p, with a volume-weighted average price of 416.58p. Following this purchase, Haleon’s registered share capital consists of 9,007,726,680 ordinary shares, with 9,003,646,475 shares carrying voting rights. This move is significant for stakeholders as it reflects Haleon’s strategic efforts to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (HLN) stock is a Buy with a $13.40 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.

Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, focused on delivering everyday health solutions with a human touch. The company offers a diverse range of products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio includes well-known brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 14,686,589

Technical Sentiment Signal: Buy

Current Market Cap: $50.21B

Learn more about HLN stock on TipRanks’ Stock Analysis page.